⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694373 | 0.69 | — | — | |
| SCHEMBL13041573 | 0.64 | — | — | |
| SCHEMBL24283595 | 0.62 | — | — | |
| SCHEMBL24758619 | 0.60 | — | — | |
| SCHEMBL24758269 | 0.58 | — | — | |
| SCHEMBL4548634 | 0.56 | — | — | |
| SCHEMBL6643230 | 0.56 | — | — | |
| SCHEMBL1617594 | 0.55 | — | — | |
| SCHEMBL17808207 | 0.54 | — | — | |
| SCHEMBL10296544 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704089-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023109909-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3988542-A1 | PYRIMIDINE DERIVATIVE INHIBITING GROWTH OF CANCER CELL AND MEDICINAL USE THEREOF | Oncobix Co.Ltd. (KR) | 2022-04-27 | — | — | EP | disclosed |
| WO-2017193063-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-01 | — | — | US | disclosed |
| WO-2015112902-A2 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-9090592-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-28 | — | — | US | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20120172376-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-07-05 | — | — | US | disclosed |